Beijing Scitop Bio-tech Co., Ltd. (SHE:300858)

Market Cap	4.82B +47.2%
Revenue (ttm)	373.31M +16.2%
Net Income	89.14M -7.3%
EPS	0.34 -8.0%
Shares Out	263.50M
PE Ratio	53.65
Forward PE	n/a
Dividend	0.10 (0.54%)
Ex-Dividend Date	Jul 16, 2025

Volume	13,263,680
Average Volume	26,823,519
Open	17.96
Previous Close	18.62
Day's Range	17.96 - 18.61
52-Week Range	13.56 - 27.08
Beta	0.36
RSI	44.68
Earnings Date	Apr 22, 2026

About Beijing Scitop Bio-tech

Beijing Scitop Bio-tech Co., Ltd. researches, develops, produces, and sells probiotic, postbiotics, and microecologival preparations for animals and plants in China. It provides probiotic and postbiotics for gastrointestinal health, immune regulation, oral health, sleep aid and stress relief, women’s health, slimming and fat reduction, kidney and liver protection, blood sugar regulation, allergy relief, blood pressure regulation, and mother-infant transmission, as well as exercise, bone, heart, and skin health applications. The company also off...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 295
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300858

Financial Performance

In 2025, Beijing Scitop Bio-tech's revenue was 365.92 million, an increase of 20.85% compared to the previous year's 302.79 million. Earnings were 94.52 million, an increase of 0.17%.